You are here

Development of Optimized AAV Serotype Vectors for Human Gene Therapy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI122735-01
Agency Tracking Number: R41AI122735
Amount: $294,094.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA14-072
Solicitation Year: 2014
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-08-09
Award End Date (Contract End Date): 2018-07-31
Small Business Information
Bloomington, IN 47401-9762
United States
DUNS: 079455600
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (317) 274-2194
Business Contact
Phone: (812) 339-3057
Research Institution

DESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune responses The main goal of the proposed research is to develop recombinant AAV vectors that are not only highly efficient but are also effective at lower doses thereby reducing the probability of inducing the host cell immune responses the vector production costs as well as the economic cost per patient for the potential gene therapy of a wide variety of human diseases Dr Arun Srivastava PI University of Florida has developed the next generation `NextGenandapos of AAV vectors by modifying the AAV capsid protein and these vectors work at significantly reduced doses and are less immunogenic His lab has also modified the AAV vector genome to develop the generation X `GenXandapos AAV vectors that further enhance the transgene expression As a result Dr Srivastava has partnered with Medosome Biotec LLC a Florida based small business focused on the development and commercialization of technologies that enrich the lives of children by providing solutions to childhood diseases disabilities and deficiencies to further develop and commercialize this vector The team hypothesizes that encapsidation of the GenX AAV genomes into NextGen AAV capsids will lead to the generation optimized andquot Optandquot AAV vectors with which significantly higher transduction efficiency at further reduced doses will be achieved The safety and efficacy of these novel OptAAV serotype vectors will be evaluated in xenograft and humanized mice models prior to their potential use in human gene therapy In the proposed Phase I STTR application the following two specific aims will be pursued Specific Aim Development of Opt AAV serotype vectors in which GenX AAV genomes are encapsidated in NextGen capsids Specific Aim Evaluation of safety and efficacy of the Opt AAV serotype vectors in xenograft and humanized murine models in vivo The successful completion of these studies will not only yield new insights into basic molecular biology of AAV but will also be directly applicable in the
further development of a vast repertoire of novel recombinant AAV serotype vectors for their optimal use in human gene therapy

PUBLIC HEALTH RELEVANCE The main aim of this proposal is to develop novel vectors with which therapeutic genes can be safely delivered to patients These vectors are derived from a virus that causes no known disease in humans and is therefore expected to be safer Thus the development of such a vector system for the potential treatment and cure of a wide variety of human disease has relevance to public health

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government